Diagnostic potency of EUS-guided FNA for the evaluation of pancreatic mass lesions

Alizadeh, Amir Houshang Mohammad; Shahrokh, Shabnam; Hadizadeh, Mohammad; Padashi, Maryam; Zali, Mohammad Reza

doi:10.4103/2303-9027.175879

Cited by 35 publications

(37 citation statements)

References 34 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adequate biopsy is still challenging because of its poor anatomic location. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is preferred for obtaining specimens for biopsy, yet its negative predictive value remains at 16-86% (Mohammad Alizadeh et al, 2016). Currently, the serum level of CA 19-9 is a widely used biomarker for the diagnosis or monitoring of PDAC, but CA19-9 alone exhibits a wide range of sensitivity (70-95%) and specificity (70-90%) (Ballehaninna and Chamberlain, 2012;Scara et al, 2015).…”

Section: Pancreatic Ductal Adenocarcinomamentioning

confidence: 99%

Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA

et al. 2019

View full text Add to dashboard Cite

Reliable biomarkers are required to evaluate and manage pancreatic ductal adenocarcinoma. Circulating tumor cells and circulating tumor DNA are shed into blood and can be relatively easily obtained from minimally invasive liquid biopsies for serial assays and characterization, thereby providing a unique potential for early diagnosis, forecasting disease prognosis, and monitoring of therapeutic response. In this review, we provide an overview of current technologies used to detect circulating tumor cells and circulating tumor DNA and describe recent advances regarding the multiple clinical applications of liquid biopsy in pancreatic ductal adenocarcinoma.

show abstract

Section: Pancreatic Ductal Adenocarcinomamentioning

confidence: 99%

Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) is able to directly extract the pancreatic tissue (3). Therefore, as it is difficult to distinguish the nature of pancreatic mass using computer tomography (CT) and EUS (4,5), EUS-FNA technology is a good option (6,7). In recent years, with the rapid development of molecular biology and high-throughput sequencing, it is possible to screen molecular markers for pancreatic cancer at the levels of genome, transcriptome and proteome.…”

Section: Introductionmentioning

confidence: 99%

Preliminary investigation of the function of hsa_circ_0006215 in pancreatic cancer

Zhu

Liu

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

The incidence of pancreatic cancer is increasing annually in Asia as a whole. Pancreatic cancer ranks sixth in terms of incidence of all malignant tumors. Circular RNA (circRNA) is a type of non-coding RNA which forms a covalently closed continuous loop. CircRNA is extensively expressed in the cytoplasm, and is markedly conservative and stable. MicroRNA (miR)-378a-3p and human (hsa)_circ_0006215 were detected using the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in tissue and cells. Western blot analysis detected the SERPINA4 and hsa_circ_0006215 expression in tissue. A Cell Counting Kit-8 assay was used to determine cell stability. Flow cytometry was used to determine the cell apoptotic rate. Transwell assays were used to determine cell migration. hsa_circ_0006215 was identified as a significantly upregulated circRNA. RT-qPCR results verified that, in 30 samples of pancreatic cancer tissue and paracancerous tissue, hsa_circ_0006215 expression was increased in pancreatic cancer tissue, miR-378a-3p expression was decreased in pancreatic cancer tissue, and SERPINA4 expression was increased in pancreatic cancer tissue (P<0.05). Using bioinformatics database and bioinformatics analysis, the interaction network of hsa_circ_0006215 indicated that this circRNA was most likely to regulate the expression of miR-378a-3p. Further interaction analysis revealed that the SERPINA4 gene was a regulatory target gene most likely to have an influence. The present study identified the effects of hsa_circ_0006215, miR-378a-3p and SERPINA4 signaling pathways in pancreatic cancer cells.

show abstract

“…Imaging is very important in the workup of periampullary cancers and is noninvasive. Mohammad Alizadeh et al [12] and Kamisawa et al [13] both found that EUS and EUS-guided FNA had good diagnostic efficacy, 85% accuracy and high sensitivity for pancreatic for cancer. Ibrahim et al [14] reported that EUS-guided FNA was not sufficiently sensitive to identify low-grade intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, or serous cystadenoma.…”

Section: Discussionmentioning

confidence: 99%

Clinical usefulness of fluorodeoxyglucose-positron emission tomography/computed tomography and carbohydrate antigen 19-9 in patients with periampullary tumors

Kim

Shin

Choi

2019

Korean J Clin Oncol

View full text Add to dashboard Cite

The prognosis of periampullary cancer varies with its origin and early diagnosis influences outcome. Endoscopic ultrasound, computed tomography, fine needle aspiration, and fluorodeoxyglucose-positron emission tomography/computed tomography (18 FDG-PET/CT) are helpful for diagnosis. This study evaluates the diagnostic efficacy of 18 FDG-PET for preoperative periampullary tumors. Methods: A series of 100 patients undergoing 18 FDG-PET/CT before surgical resection of periampullary tumors between March 2011 and February 2019 were enrolled. Maximum standardized uptake value (SUVmax) and carbohydrate antigen 19-9 (CA19-9) levels were compared with pathohistological confirmation of periampullary tumors. Results: The SUVmax and uptake range varied with the origin of the periampullary tumors. The SUVmax was not available for 17 of the 42 pancreas tumors, three of 30 common bile duct tumors, and four of 18 ampulla of Vater tumors. The median SUVmax was 0.0 in benign tumors and 5.05 in malignant tumors. The mean SUVmax was 4.1±5.6 in pancreatic tumors, 3.9±2.4 in ampulla of Vater, and 6.0±3.7 in common bile duct. The SUVmax was higher in common bile duct tumors than others. CA19-9 level was of diagnostic value in pancreatic tumor patients. The median CA19-9 levels were 7.64 U/mL (range, 2.71-45.05 U/mL) in benign tumors and 91.97 U/mL (range, 26.91-276.60 U/ mL) in cancers patients. Conclusion: Preoperative SUVmax and CA19-9 level were of diagnostic value for periampullary tumors originating in the pancreas.

show abstract

Diagnostic potency of EUS-guided FNA for the evaluation of pancreatic mass lesions

Cited by 35 publications

References 34 publications

Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA

Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA

Preliminary investigation of the function of hsa_circ_0006215 in pancreatic cancer

Clinical usefulness of fluorodeoxyglucose-positron emission tomography/computed tomography and carbohydrate antigen 19-9 in patients with periampullary tumors

Contact Info

Product

Resources

About